Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer

Molecular Detection of Circulating Cancer Cells in Breast, Ovarian, Colon and Pancreatic Cancer

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00898781

Enrollment

Registered

2009-05-12

Start date

2007-11-30

Completion date

2010-04-30

Last updated

2011-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer

Keywords

male breast cancer, stage IV breast cancer, stage IV ovarian epithelial cancer, stage IV ovarian germ cell tumor, stage IV pancreatic cancer, stage IV colon cancer, ovarian sarcoma

Brief summary

RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients with metastatic cancer may help doctors find out how much the cancer has spread. PURPOSE: This research study is looking at the number of circulating cancer cells in patients with metastatic breast cancer, ovarian cancer, colon cancer, or pancreatic cancer.

Detailed description

OBJECTIVES: * To assess frequency of circulating tumor cells (CTCs) in patients with metastatic ovarian, breast, pancreatic, and colon cancers. * To assess the variability in number of CTCs between patients with the same tumor type. * To correlate the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers. OUTLINE: Blood samples are collected before treatment and analyzed using molecular detection techniques to detect circulating cancer cells. Samples are assessed by immunofluorescence for markers of proliferation and survival (e.g., EGFR, phosphorylated EGFR, AKT, phosphorylated AKT, cytokeratins, MAPK, Src, and FAK).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Radiographic or marker evidence of metastatic ovarian, breast, pancreatic, or colon disease * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * No history of any prior cancer PRIOR CONCURRENT THERAPY: * No prior therapy for metastatic disease

Design outcomes

Primary

Measure	Time frame
Frequency of circulating cancer cells (CTC)	1 day
Variability in number of CTCs between patients with the same tumor type	1 day
Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers	1 day

Countries

United States

Outcome results